Navigation Links
Study Aims At The Immune System In Patients With Lou Gehrig's Disease

Carolyn Shimek takes cholesterol-decreasing medications like millions of Americans. However she does not have high cholesterol like others//. This is since she is taking part in a different clinical study found only at the Methodist Neurological Institute (NI) to view the benefits of Lipitor on the immune system in patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS).

Physicians at the Methodist NI's MDA/ALS Clinical Center diagnosed the 48-year-old Victoria, Texas resident in 2005. When she learned of this investigator-initiated research, Shimek knew she had to give it a chance.

‘I have a lot to live for - my family and friends,’ said Shimek, a wife, mother of three, and one of 12 siblings. ‘If participating in this study means it will help me or other ALS patients down the road then it's worth it.’

Dr. Ericka Simpson, co-director of Methodist's ALS Clinic, is the primary investigator who oversees this double-blind study in which patients will be randomly assigned to receive the drug or a placebo. Simpson believes the immune system plays an important role in how ALS affects patients.

‘Lipitor has been shown to regulate immune responses that may provide protection in diseases of the central nervous system. Our goal is to determine whether Lipitor has the ability to improve the course of disease progression and quality of life for our ALS patients,’ said Simpson.

Currently, the only FDA-approved drug therapy for ALS is Rilutek. The drug has been shown to modestly improve patient survival, but has no measurable affect on function or the rate of disease progression. ALS is a progressive neurodegenerative disease characterized by degeneration of the upper and lower motor neurons in the brain and spinal cord which stimulate skeletal muscle movement. As more motor neurons die, muscle weakness gets progressively worse. An estimated 30,000 people throughout the U.S. have ALS, and 8,000 new cas es are diagnosed each year.

Source: Neswise
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... April 21, 2017 , ... ... named Agency of Record (AOR) for Theravent, Inc. , the makers of ... parent company, Foundation Consumer Healthcare, is now working to expand distribution in anticipation ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... is seeking candidates to serve on its Accreditation and Standards Committees to ... ultimate mission is improving image quality and reducing patient radiation dose,” reports ...
(Date:4/21/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, wrote an open letter this ... to peace plan. Yisrayl says war has never brought peace and he knows the only ... , Yisrayl says war drums are beating all over the media and the tensions ...
(Date:4/21/2017)... ... April 21, 2017 , ... A ... for older shoulder replacement patients; post-operative recovery just might be even better than ... patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 patients ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: